Could one blood thinner be enough after a heart attack? new trial aims to find out
NCT ID NCT07583784
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study compares two approaches to blood thinning after a heart attack in patients with atrial fibrillation. One group gets two blood thinners (a DOAC plus clopidogrel), while the other gets only one (a DOAC alone). The goal is to see if using just one drug reduces bleeding risks without increasing the chance of another heart attack or stroke. About 860 adults will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Direct oral anticoagulants (apixaban, edoxaban, or rivaroxaban) with or without clopidogrel
What this could lead to
If successful, this could show that using only one blood thinner is safer and just as effective as two after a heart attack in people with atrial fibrillation, potentially reducing bleeding complications.
What could go wrong
This is a relatively early-stage trial with 860 participants, and the results may not apply to all patients. There is a risk that single therapy might not prevent future heart attacks or strokes as well as dual therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYOCARDIAL INFARCTION (MI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chonnam National University Hospital
Gwangju, Gwangju, 61469, South Korea
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact